Cortagen is a short synthetic peptide from the Khavinson “bioregulator” family, marketed as a cerebral cortex / neuro regulator. It is sold mainly as an oral capsule by longevity and biohacking resellers, and should not be confused with Cortexin, a different and separately marketed cattle-brain-extract product sometimes discussed alongside it.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” tetrapeptide, marketed as a cerebral cortex/neuro regulator |
| Primary research interest | Cerebral cortex tissue support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — sequence repeated fairly consistently across reseller sites but could not be confirmed against an independent primary chemical database (no verifiable CAS, PubChem CID, or UNII record located) |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold mainly as an oral capsule by longevity/biohacking resellers |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Cortagen |
| Alternative names | Not to be confused with Cortexin, a different, separately marketed cattle-brain-extract product |
| Peptide sequence | Most commonly given by vendors as Ala-Glu-Asp-Pro (“AEDP”); widely repeated across reseller sites but not independently confirmed against a primary chemical database |
| Amino-acid length | 4 (tetrapeptide, per vendor description) |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | No verifiable CAS number located |
| PubChem CID | No verifiable PubChem CID located |
| Peptide class | Khavinson-group “bioregulator” peptide line |
| Primary biological target | Not established — proposed cerebral cortex tissue activity, not confirmed via primary literature |
| Developer or originator | Vladimir Khavinson’s laboratory, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Cortagen is part of the same short-peptide bioregulator concept originated by Vladimir Khavinson’s laboratory, proposed to act on cerebral cortex tissue specifically. Vendor listings most commonly give the sequence as the tetrapeptide Ala-Glu-Asp-Pro (AEDP). This sequence is repeated fairly consistently across a number of reseller sites, though PeptideBlog.net was unable to confirm it against an independent primary chemical database — no verifiable CAS number, PubChem CID, or UNII record was located, so it is treated as widely repeated rather than independently confirmed.
Cortagen is not the same product as Cortexin, an injectable cattle-brain-peptide-extract preparation that is registered as a pharmaceutical in Russia and some CIS countries for neurological indications; the two are sometimes conflated by resellers and in casual online discussion because both target the brain and share a similar-sounding name, but they come from different manufacturing processes (short synthetic peptide vs. animal tissue extract) and different regulatory histories.
Cortagen has not been evaluated or approved by the FDA or any Western regulatory body, and it does not appear to hold independent pharmaceutical registration in Russia; it is sold as a supplement.
How does it work?
Plain-English explanation
The proposed idea is that Cortagen supports normal cerebral cortex cell function, potentially relevant to cognitive aging, based on the general bioregulator hypothesis applied to brain tissue. This has not been demonstrated in controlled human studies.
Technical explanation
As with other members of this peptide family, the proposed mechanism involves short-peptide interaction with chromatin/gene-regulatory elements in cortical neurons or glia. This is the developers’ own theoretical framework; independent groups have not published confirmatory mechanistic work specific to Cortagen, and no pharmacokinetic data for oral use (including whether it could plausibly cross the blood-brain barrier in meaningful amounts) was identified.
Potential benefits and research applications
Cognitive and cortical-aging support
What is being investigated: whether Cortagen supports normal cognitive function or cortical tissue health with age, per developer materials. How the effect might occur: proposed gene-regulatory action in cortical cells. Evidence: limited animal/mechanistic work from the originating Russian research group; independent replication was not identified. Strength: weak (Tier 3/4 at best). Limitation: no controlled human cognitive-outcome data was found, and there is no established mechanism by which an orally administered short peptide would meaningfully reach cortical tissue.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. General references to Khavinson-group rodent aging/cognition studies exist in secondary sources, but specific extractable dose figures for Cortagen were not identified.
Practitioner and community-reported protocols
Vendor pages commonly describe 10-20 mg oral capsules, one capsule daily, in cycles of roughly 10-20 days. This is vendor/community-reported (Tier 6) information, not a clinical protocol, and its original source could not be traced to any published study.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General cognitive/cortical-aging support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days.
This is widely repeated online, but its original source could not be verified against any published clinical protocol.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. General risks applicable to unregulated peptide supplements apply: unverified purity and identity, uncertain oral bioavailability, no long-term safety monitoring, and supply-chain risks such as mislabeling or incorrect concentration. Consumers should also be aware of the separate Cortagen/Cortexin naming confusion, since the two are different products with different safety profiles and regulatory status.
Regulatory and developmental status
Cortagen is not FDA approved and has no FDA-recognized indication. No independent pharmaceutical registration was identified in Russia; it circulates as a supplement. Status verified as of the review date below.
Frequently asked questions
What is Cortagen?
Cortagen is a short Khavinson-family synthetic peptide marketed as a cerebral cortex bioregulator, sold mainly as an oral supplement.
Is Cortagen the same as Cortexin?
No. Cortexin is a separate, animal-tissue-extract product with its own regulatory history in some countries; Cortagen is a short synthetic peptide sold as a supplement. The two are sometimes confused because of the similar name and shared brain-related marketing.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days; this is vendor/community-reported, not a clinical dose.
Is Cortagen approved by any regulator?
No. No FDA or other formal regulatory approval was identified.
Bottom line
Cortagen is another thinly documented Khavinson-family peptide, distinct from the separately marketed Cortexin product despite the similar name. Its published support is limited to animal/mechanistic work from the originating research group, with no independent human clinical evidence, no confirmed chemical identifiers, and no established route by which an oral capsule would reach cortical tissue in meaningful amounts.